SCHEMBL23218234

SCHEMBL23218234

COC(=O)c1cc(I)c2oc(COc3ccccc3CC(=O)OC(C)(C)C)cc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 5/20 0.38
MTNR1B P49286 5/20 0.38
LMNA P02545 2/20 0.34
ALDH1A1 P00352 1/20 0.34
KDM4E B2RXH2 1/20 0.34
GAA P10253 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
MAPT P10636 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
TSHR P16473 1/20 0.32
KMT2A Q03164 1/20 0.32
HSD17B10 Q99714 1/20 0.32
PPARD Q03181 2/20 0.32
HPGD P15428 1/20 0.32
STAT3 P40763 1/20 0.32
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
ESR1 P03372 1/20 0.31
THRA P10827 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23219131 0.91 MTNR1A (0.37) MTNR1AMTNR1BLMNAHDAC6MAPT
SCHEMBL23218390 0.86 ACACB (0.42) KDM4EHDAC6
SCHEMBL29853205 0.86 ACACB (0.42) KDM4EHDAC6
SCHEMBL29853074 0.85 MTNR1A (0.37) MTNR1AMTNR1BLMNAALDH1A1SMN1; SMN2
SCHEMBL29853229 0.85 MTNR1A (0.37) MTNR1AMTNR1BLMNAALDH1A1KDM4E
SCHEMBL23218702 0.85 MTNR1A (0.37) MTNR1AMTNR1BLMNAALDH1A1SMN1; SMN2
SCHEMBL23218235 0.85 MTNR1A (0.37) MTNR1AMTNR1BLMNAALDH1A1KDM4E
SCHEMBL23218513 0.84 MTNR1A (0.36) MTNR1AMTNR1BLMNAALDH1A1KDM4E
SCHEMBL23218512 0.84 MTNR1A (0.36) MTNR1AMTNR1BLMNAALDH1A1L3MBTL1
SCHEMBL29852636 0.84 MTNR1A (0.36) MTNR1AMTNR1BLMNAALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB MTNR1A 3930/4885MTNR1B 3580/4885LMNA 1698/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB MTNR1A 3848/4885MTNR1B 2984/4885LMNA 1844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.